Breaking News

Trials & Filings in Brief: Nov. 18, 2013

By Gil Roth | November 18, 2013

AbbVie, ChanRx, Enanta, Gilead, Merck, Sanofi

Phase II
ChanRx posts positive A-Fib data . . . read more

Phase III
AbbVie, Enanta show HCV results . . . read more

Gilead gets EC approval for Vitekta . . . read more

Merck's Noxafil IV gets priority review . . . read more

Sanofi ends JAK2 development . . . read more
  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials